Erythropoietin therapy in patients with chronic renal failure.
AUTOR(ES)
Pinevich, A J
RESUMO
Symptomatic anemia is a common complication of chronic renal failure. Treatment is now possible with the availability of recombinant human erythropoietin (epoetin alfa). Previous experimental studies have suggested that correcting the anemia of chronic renal failure may be harmful in that renal failure may be accelerated. Although experience with this drug has been primarily restricted to its use in patients with end-stage renal disease, several recent trials have been reported in patients with varying degrees of chronic renal failure. We review these studies with particular reference to the progression of renal failure and the drug's reported side effects. We conclude that the use of epoetin is beneficial and well tolerated and that there is no compelling evidence for the acceleration of renal failure associated with its use in patients.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1011236Documentos Relacionados
- Plasma erythropoietin assay in patients with chronic renal failure.
- Cellular bioenergetics after erythropoietin therapy in chronic renal failure.
- Proceedings: Plasma erythropoietin values in patients with renal failure.
- Amyloid arthropathy in patients with chronic renal failure.
- Effects of erythropoietin on muscle O2 transport during exercise in patients with chronic renal failure.
